ACADIA PHARMACEUTICALS INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ACAD in the last 30 days.
See all $ACAD insider activity →Analysts showed selective bullishness on Sept 25, 2026, with positive calls in tech, healthcare, and industrials. 3M (MMM) was upgraded to Market Perform with a $171 target. ACADIA (ACAD) saw multiple target cuts. Akamai (AKAM) received several target raises. Apple (AAPL) kept Outperform. Chevron (CVX) target raised to $250. Costco (COST) had mixed ratings.
H.C. Wainwright lowered its price target on Acadia Pharmaceuticals (ACAD) to $33 from $37, citing a Phase 2 trial miss. The stock fell 22% to $20.68. Despite this, some analysts see value, with price targets up to $49. The trial missed its primary endpoint but hit a key secondary endpoint.
ACADIA PHARMACEUTICALS INC (ACAD) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP) — Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 develop
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning ACAD (ACADIA PHARMACEUTICALS INC). Coverage has skewed bearish: 0 bullish, 0 neutral, and 4 bearish.
Recent ACAD coverage spans technology, market movers and financial news.
Target cuts signal weaker expectations.
Target cut and trial miss suggest near‑term downside pressure.
Positive Phase 2 data may lift ACAD stock and support continued Phase 3 enrollment.
Sell-side downside framing intensifies after Phase 2 primary endpoint miss, even as Acadia plans to proceed with Phase 3 using secondary/exploratory signals.
Target reduction signals near‑term downside pressure on ACAD.
AlphAI scores every news story that mentions ACAD with an AI model for sentiment and relevance, and aggregates insider trades from ACADIA PHARMACEUTICALS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Analysts showed selective bullishness on Sept 25, 2026, with positive calls in tech, healthcare, and industrials. 3M (MMM) was upgraded to Market Perform with a $171 target. ACADIA (ACAD) saw multiple target cuts. Akamai (AKAM) received several target raises. Apple (AAPL) kept Outperform. Chevron (CVX) target raised to $250. Costco (COST) had mixed ratings.
3 min readH.C. Wainwright lowered its price target on Acadia Pharmaceuticals (ACAD) to $33 from $37, citing a Phase 2 trial miss. The stock fell 22% to $20.68. Despite this, some analysts see value, with price targets up to $49. The trial missed its primary endpoint but hit a key secondary endpoint.
2 min readACADIA PHARMACEUTICALS INC (ACAD) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP) — Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 develop
2 min readGoldman Sachs reiterated a Sell rating and $17.00 price target on Acadia Pharmaceuticals (ACAD) after its Phase 2 trial for remlifanserin missed the primary endpoint. The stock trades at $22.77, above Goldman's target but below the highest analyst estimate. Acadia plans to continue Phase 3 trials with amendments. Analysts have mixed views, with some revising earnings upwards and others lowering price targets.
5 min readBMO Capital reduced its price target for Acadia Pharmaceuticals (ACAD) to $34, citing a trial miss, but maintained an Outperform rating. The stock is down 7.4% over the past week. The firm lowered the success probability for the drug candidate to 35% from 40%. Acadia generated $1.14 billion in revenue over the last twelve months and has a market cap of $3.93 billion.
2 min readAcadia Pharmaceuticals' (ACAD) experimental Alzheimer's drug, remlifanserin, missed statistical significance in a Phase 2 study. The drug aimed to improve hallucinations and delusions in Alzheimer's patients. The stock fell after the news.
1 min readAcadia Pharmaceuticals reported that its experimental drug for Alzheimer's psychosis, remlifanserin, missed the main goal of a mid-stage study. The 60-mg dose showed improvement over placebo but not enough to meet the primary endpoint. The 30-mg dose showed little benefit. Despite this, Acadia will continue late-stage studies, removing the 30-mg arm. The company expects peak sales of $4 billion. Analysts suggest a potential path forward.
2 min readACADIA Pharmaceuticals' stock fell 8.1% in pre-market trading after its Phase 2 trial for remlifanserin narrowly missed the primary endpoint, though it met a key secondary endpoint. The company will continue Phase 3 studies, removing the 30 mg dosage arm. CEO Catherine Owen Adams stated the data support the Phase 3 program. The stock is trading at $23.36, below its 52-week high of $30.96.
2 min readAcadia Pharmaceuticals (ACAD) reported Phase 2 results for remlifanserin in treating Alzheimer’s disease psychosis. The 60 mg dose showed efficacy vs. placebo, while the 30 mg dose did not. The company plans to continue Phase 3 trials, focusing on the 60 mg dose. Remlifanserin demonstrated a favorable safety profile. Acadia will present detailed results at the CTAD conference in November 2026.
2 min readU.S. stock futures fell as bond yields rose. Grail (GRAI) gained 11.3% after FDA panel support for its cancer test. Stitch Fix (SFIX) dropped 18.4% on weak revenue outlook. MGM (MGM) fell 8.3% after a buyout offer withdrawal. Darden (DRI) declined 4.1% on weak Olive Garden sales. BlackBerry (BB) rose 4.1% ahead of earnings. Everpure (EVR) gained 7.1% on upbeat long-term outlook. Greenland Mines (GDLNF) surged 19% after $42M stock offering. Acadia (ACAD) fell 6% on mixed drug trial results.
3 min read
